Holen Sie sich die Stockscreener-App
4.61
5.73%
0.25
Schlusskurs vom Vortag:
$4.36
Offen:
$4.37
24-Stunden-Volumen:
112.65K
Relative Volume:
1.05
Marktkapitalisierung:
$38.27M
Einnahmen:
$140.46M
Nettoeinkommen (Verlust:
$-146.34M
KGV:
-3.6299
EPS:
-1.27
Netto-Cashflow:
$-117.73M
1W Leistung:
+2.67%
1M Leistung:
+11.89%
6M Leistung:
-62.13%
1J Leistung:
-61.58%
1-Tages-Spanne:
$4.30
$4.85
1-Wochen-Bereich:
$4.25
$4.85
52-Wochen-Spanne:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Vergleichen Sie KPTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
4.61 | 38.27M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Acquired by Two Sigma Investments LP - Defense World
Class Action ReminderNFLX, KPTI & MNKBronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Two Sigma Advisers LP Buys 45,400 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Millennium Management LLC Lowers Stock Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Karyopharm at Jefferies: Pioneering Trials in Cancer Treatment By Investing.com - Investing.com Nigeria
Karyopharm at Jefferies: Pioneering Trials in Cancer Treatment - Investing.com Australia
Karyopharm to Present at the Jefferies Global Healthcare Conference - Kilgore News Herald
Karyopharm to Present at the Jefferies Global Healthcare Conference | KPTI Stock News - GuruFocus
Northern Trust Corp Acquires 54,061 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KPTI Stock News - GuruFocus
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Acquired by Jane Street Group LLC - Defense World
Karyopharm increases share reserve for equity plan - Investing.com India
Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment - TipRanks
Karyopharm increases share reserve for equity plan By Investing.com - Investing.com UK
D. E. Shaw & Co. Inc. Sells 817,711 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Hepatic Impairment Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Novartis, ApoPharma, Indivior Inc., Boehringer Ingelheim, Ocera Therapeutics, Orient Europharma, Karyopharm - Barchart.com
Focus Partners Wealth Makes New Investment in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Karyopharm Therapeutics’ SWOT analysis: oncology firm’s stock faces pivotal year - Investing.com India
Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27% - simplywall.st
Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet - simplywall.st
Karyopharm at RBC Capital Markets: Strategic Insights on XPOVIO and Pipeline - Investing.com Australia
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference - Eastern Progress
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect? - sharewise
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference | KPTI Stock News - GuruFocus
StockNews.com Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell - Defense World
Leerink Partnrs Issues Positive Estimate for KPTI Earnings - Defense World
Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $45.60 - Defense World
Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion - MSN
Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains - TipRanks
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2025 Earnings Call Transcript - Insider Monkey
Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - Defense World
Karyopharm Announces Poster Presentation on Selinexor in Myelofi - GuruFocus
KPTI to Present Promising Selinexor Data at Upcoming Hematology Meeting | KPTI Stock News - GuruFocus
Karyopharm abstract selected for presentation at 2025 EHA meeting - TipRanks
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting - PR Newswire
KPTI: RBC Capital Lowers Price Target while Maintaining Outperform Rating | KPTI Stock News - GuruFocus
RBC Capital cuts Karyopharm stock price target to $33 By Investing.com - Investing.com Canada
KPTI: RBC Capital Lowers Price Target while Maintaining Outperfo - GuruFocus
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Benzinga
KPTI Misses Q1 Revenue Estimates but Advances Myelofibrosis Tria - GuruFocus
KPTI Stock Boosted as Barclays Raises Price Target to $10 | KPTI - GuruFocus
Karyopharm (KPTI) Target Price Reduced by RBC Capital | KPTI Sto - GuruFocus
KPTI: Baird Lowers Price Target but Maintains Outperform Rating - GuruFocus
Karyopharm (KPTI) Price Target Reduced by Baird, Outperform Rati - GuruFocus
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Karyopharm Therapeutics Inc-Aktie (KPTI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rangwala Reshma | EVP & Chief Medical Officer |
Apr 23 '25 |
Sale |
6.17 |
419 |
2,585 |
28,853 |
| Paulson Richard A. | President and CEO |
Apr 04 '25 |
Sale |
3.74 |
245 |
916 |
82,739 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Mar 04 '25 |
Sale |
6.29 |
3,445 |
21,669 |
34,314 |
| Paulson Richard A. | President and CEO |
Mar 04 '25 |
Sale |
6.29 |
11,694 |
73,555 |
82,984 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 04 '25 |
Sale |
6.29 |
3,587 |
22,562 |
29,272 |
| Poulton Stuart | EVP, Chief Development Officer |
Mar 04 '25 |
Sale |
6.29 |
3,548 |
22,317 |
27,414 |
| Mano Michael | SVP, General Counsel&Secretary |
Mar 04 '25 |
Sale |
6.29 |
2,793 |
17,568 |
21,047 |
| Poulton Stuart | EVP, Chief Development Officer |
Feb 18 '25 |
Sale |
0.63 |
5,914 |
3,726 |
320,714 |
| Paulson Richard A. | President and CEO |
Feb 04 '25 |
Sale |
0.65 |
4,099 |
2,664 |
1,120,158 |
| Paulson Richard A. | President and CEO |
Jan 06 '25 |
Sale |
0.78 |
4,055 |
3,175 |
1,124,257 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):